donepezil transdermal patch (DA-5207) / Dong-A - LARVOL DELTA

Phase 1 Clinical Trial of DA-5207 in Healthy Adults (clinicaltrials.gov) - P1 | N=51 | Completed | Sponsor: Dong-A ST Co., Ltd. | Not yet recruiting ➔ Completed | Trial primary completion date: Apr 2022 ➔ Dec 2022

Trial completion • Trial primary completion date

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD Profiles of DA-5207 TDS in Healthy Adults (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Dong-A ST Co., Ltd.

Clinical • New P1 trial

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults (clinicaltrials.gov) - P1; N=49; Active, not recruiting; Sponsor: Dong-A ST Co., Ltd.; Not yet recruiting ➔ Active, not recruiting

Enrollment closed

Single-ascending Dose Phase 1 Clinical Trial to Evaluate the Safety and PK of DA-5207 TDS in Healthy Adults (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Dong-A ST Co., Ltd.; Recruiting ➔ Completed

Trial completion

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Dong-A ST Co., Ltd.

Clinical • New P1 trial

Dong-A ST posts robust profit in 2019 (Korea Biomedical Review) - "The company said that it has completed its U.S. phase 2a clinical trial for DA-9805, a Parkinson's disease treatment...Also, the company plans to complete its local phase 1 clinical trial for DA-5207, a weekly patch-type dementia treatment, in the first half of this year. At the same time, it has received approval to conduct a phase 1 clinical trial for the drug candidate in India. It said DA-9801, a diabetic neuropathy treatment licensed out to NeuroBo, will be tested soon in a phase 3 trial in the U.S."

New P3 trial • Trial completion • Trial status